期刊
VACCINES
卷 9, 期 11, 页码 -出版社
MDPI
DOI: 10.3390/vaccines9111297
关键词
SARS-CoV-2; COVID-19 pandemic; COVID-19; SARS-CoV-2; vaccine; Pfizer-BioNTech; side effects; children
资金
- Deanship of Scientific Research, Jazan University, Jazan, Saudi Arabia [Cov19-56]
- Deanship of Scientific Research at Jazan University
This study aimed to investigate the early side effects of the Pfizer-BioNTech (BNT162b2) mRNA vaccine in children aged 12-18 years in Saudi Arabia. Results showed that 60% of the participants reported at least one side effect, with pain or redness at the injection site, fatigue, fever, and headache being the most frequently reported. Female participants reported side effects more frequently than male participants, and side effects were more common after the second dose of the vaccine.
Background: Massive vaccination campaigns have been undertaken globally to combat the spread of the Coronavirus Disease 2019 (COVID-19). While most COVID-19 vaccines have shown excellent efficacy and safety profiles in clinical studies, real-world monitoring of vaccine safety is still important. In this study, we aimed to investigate the early side effects of Pfizer-BioNTech (BNT162b2) mRNA vaccine in children between 12-18 years old in Saudi Arabia. Method: To investigate the side effects in children in this age range following the administration of either one or two doses of Pfizer-BioNTech (BNT162b2) mRNA vaccine, we conducted a retrospective, cross-sectional study using a self-administered online survey. General and demographic data were collected, and vaccineassociated side effects following vaccination were evaluated. Results: The study recruited a total of 965 eligible participants. Overall, 571 (60%) of the study participants reported at least one side effect following Pfizer-BioNTech (BNT162b2) mRNA vaccination. The most frequently reported side effects were pain or redness at the site of injection (90%), fatigue (67%), fever (59%), headache (55%), nausea or vomiting (21%), and chest pain and shortness of breath (20%). Joint or bone pain were reported less frequently among our participants (2%). Our data showed that more female participants reported side effects compared to male participants, with 52% and 48%, respectively. Side effects were more common after the second dose compared to the first dose in our study cohort. Conclusions: While 60% of the children (12-18 years old) who received Pfizer-BioNTech (BNT162b2) mRNA vaccine reported side effects, our data showed that these side effects were not different from those that were reported in the clinical trials which lasted only for a few days. Side effects were more common after the second dose. Larger epidemiological and molecular studies are needed to evaluate the safety and the effectiveness of COVID-19 vaccine in protection of children against SARS-CoV-2 reinfections.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据